Search Result

Results for "

IAV

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AP-1 (1) Apoptosis (1) Bacterial (1) COX (1) Dipeptidyl Peptidase (1) EGFR (1) Endogenous Metabolite (2) HSV (1) Influenza Virus (32) Interleukin Related (1) MHC (2) Mixed Lineage Kinase (1) Necroptosis (1) NF-κB (2) NO Synthase (1) PROTACs (2) Reactive Oxygen Species (ROS) (1) Reference Standards (1) RIG-I-like receptor (RLR) (2) RIP kinase (2) RSV (6) SARS-CoV (14) STAT (1) TGF-β Receptor (1) Toll-like Receptor (TLR) (1) TRP Channel (1)
By Research Areas:	Cancer (5) Infection (44) Inflammation/Immunology (6) Neurological Disease (2)

By Targets:

AP-1 (1)

Apoptosis (1)

Bacterial (1)

COX (1)

Dipeptidyl Peptidase (1)

EGFR (1)

Endogenous Metabolite (2)

HSV (1)

Influenza Virus (32)

Interleukin Related (1)

MHC (2)

Mixed Lineage Kinase (1)

Necroptosis (1)

NF-κB (2)

NO Synthase (1)

PROTACs (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

RIG-I-like receptor (RLR) (2)

RIP kinase (2)

RSV (6)

SARS-CoV (14)

STAT (1)

TGF-β Receptor (1)

Toll-like Receptor (TLR) (1)

TRP Channel (1)

By Research Areas:

Cancer (5)

Infection (44)

Inflammation/Immunology (6)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128965

N-Glycolylneuraminic acid NeuGc; GcNeu	Influenza Virus Endogenous Metabolite	Infection Cancer
N-Glycolylneuraminic acid is a nonhuman sialic acid molecule synthesized in pigs but not in humans. N-Glycolylneuraminic acid works as a decoy receptor of N-Glycolylneuraminic acid-binding influenza A viruses (IAVs) .

HY-134608

Cobalt protoporphyrin IX Co-PPIX	Reactive Oxygen Species (ROS) Influenza Virus	Infection
Cobalt protoporphyrin IX (Co-PPIX) is a potent and specific heme oxygenase-1 (HO-1) inducer. Cobalt protoporphyrin IX exhibits broad-spectrum antiviral activities against Influenza A virus (IAV) .

HY-175469

VNT-101	Influenza Virus	Infection
VNT-101 is an orally active influenza A (IAV) inhibitor. VNT-101 disrupts NP-NP PPI to block NP oligomerization and destabilize the viral ribonucleoprotein (RNP) complex, with potent antiviral activity across multiple influenza A subtypes. VNT-101 exhibits EC₅₀ values of 4-5 nM in cellular cytopathic effect (CPE) assay, 4-8 nM in neuraminidase (NA) assay, and 21-45 nM in RNP assay. VNT-101 demonstrates robust in vivo antiviral efficacy in mice infected with lethal H1N1 virus. VNT-101 can be used for the study of influenza A infection .

HY-P99637

Gedivumab MHAA4549A; RG7745	Influenza Virus	Infection
Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .

HY-W031757

Anthraquinone-2-carboxylic acid	Influenza Virus Bacterial Dipeptidyl Peptidase COX NF-κB AP-1 RIG-I-like receptor (RLR) STAT	Infection Neurological Disease Inflammation/Immunology
Anthraquinone-2-carboxylic acid is an orally active anthraquinone compound and Antibacterial agent. Anthraquinone-2-carboxylic acid can be isolated from Bajitian. Anthraquinone-2-carboxylic acid inhibits the activation of DPP-IV, COX-2, NF-κB and AP-1. Anthraquinone-2-carboxylic acid blocks IAV-induced activation of the RIG-I/STAT1 pathway, alleviates IAV-mediated weight loss, and protects against lethal IAV infection. Anthraquinone-2-carboxylic acid inhibits the growth of various Staphylococcus strains. It possesses potent anti-inflammatory, immunomodulatory, analgesic and antibacterial activities .\n

HY-158312

UH15-38 1 Publications Verification	Necroptosis RIP kinase Influenza Virus	Infection Inflammation/Immunology
UH15-38 is a potent RIPK3 inhibitor with an IC₅₀ value of 20 nM. UH15-38 blocks IAV (influenza A virus)-activated necroptosis. UH15-38 dampens IAV-induced lung injury .

HY-N0891

Tubeimoside II Tubeimoside-B	EGFR TGF-β Receptor RIG-I-like receptor (RLR) SARS-CoV	Infection Neurological Disease Cancer
Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with K_d values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43, and *IAV-H1N1/FM1*. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections, skin tumors, and sarcoma 180 .

HY-156048

Trifluoromethyl-tubercidin 2 Publications Verification TFMT	Influenza Virus	Infection
Trifluoromethyl-tubercidin (TFMT) is an inhibitor of 2'-O-ribose methyltransferase 1 (MTr1). Trifluoromethyl-tubercidin can inhibit the replication of influenza A and B viruses by interfering with the cap-snatching process of the influenza virus. Trifluoromethyl-tubercidin has antiviral activity and low toxicity .

HY-P99620

Firivumab CT-P22; CT120	Influenza Virus	Infection
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal *influenza A virus hemagglutinin (Anti-IAV* HA)** antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .

HY-177119

ZBP1 Covalent PROTAC-1	PROTACs RIP kinase Mixed Lineage Kinase	Infection Inflammation/Immunology
ZBP1 Covalent PROTAC-1 is a covalent Z-DNA binding protein 1 ZBP1 PROTAC degrader, with its DC₅₀ being 25.69 nM. ZBP1 Covalent PROTAC-1 integrates the ligand that recruits the VHL E3 ubiquitin ligase and the DNA aptamer (Aptamer Z3) with the specific Zα domain that can bind to ZBP1, which has a high affinity (K_D = 2.71 nM) with ZBP1. After degrading ZBP1, the phosphorylation levels of downstream signaling molecules RIPK3 and MLKL significantly decrease. ZBP1 Covalent PROTAC-1, encapsulated by nano-liposomes, significantly improves the survival rate of mice infected with influenza A virus (IAV) after administration via the trachea .

HY-P990187

Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114)	MHC Influenza Virus	Infection Inflammation/Immunology
Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse MHC Class II. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) reacts with mouse MHC Class II haplotypes I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) does not react with I-Af, I-Ak, or I-As haplotypes. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) blocks MHC Class II and inhibit T cell generation. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) can be used for the researches of infection and immunology, such as influenza A virus (IAV) infection .

HY-143494

*RSV/IAV-IN-3*	RSV Influenza Virus	Infection
RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC₅₀ values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC₅₀ values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC₅₀ of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage .

HY-124449

Afidopyropen ME-5343	TRP Channel	Others
Afidopyropen (ME-5343) is an Afidopyropen targets sucking insects such as whiteflies, aphids, and leafhoppers by acting on the Nanchung (Nan) and Inactive (Iav) encoding gene of insects, and affecting TRPV channel. Afidopyropen can be used for many crops for its degradability .

HY-P990188

Anti-Mouse MHC class II (I-A) Antibody (Y-3P)	MHC	Inflammation/Immunology
Anti-Mouse MHC class II (I-A) Antibody (Y-3P) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse MHC class II. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) reacts with mouse MHC Class II haplotypes I-Ab, I-Af, I-Ap, I-Aq, I-Ar, I-As, I-Au, I-Av, and weakly with I-Ak. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) blocks MHC class II and inhibits expansion of regulate T cells. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) can be used for the immunology research .

HY-161820

IAV-IN-3	Influenza Virus	Infection
IAV-IN-3 (Compound (R,S)-16s) is an anti-influenza A virus (IAV) agent (EC₅₀ = 0.134 μM) with weak cytotoxicity (CC₅₀ = 15.35 μM for MDCK cells). IAV-IN-3 inhibits IAV polymerase with an IC₅₀ of 0.045 μM .

HY-130627

*RSV/IAV-IN-2*	RSV Influenza Virus	Infection
RSV/IAV-IN-2 (compound 14c) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-2 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-2 has the potential for the research of RSV and/or IAV infections .

HY-130626

*RSV/IAV-IN-1*	RSV Influenza Virus	Infection
RSV/IAV-IN-1 (compound 14e) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-1 has lesser cytotoxicity than the clinical agent, Ribavirin. RSV/IAV-IN-1 has the potential for the research of RSV and/or IAV infections .

HY-151967

*Anti-IAV* agent 1**	Influenza Virus	Infection
Anti-IAV agent 1 (Compound (R)-1a) is an orally active anti-influenza A virus (IAV) agent with IC₅₀s of 0.03 and 0.06 μM against IAV H1N1 and Oseltamivir-resistant IAV H1N1 strains, respectively .

HY-131179

Influenza A virus-IN-1	Influenza Virus	Infection
Influenza A virus-IN-1 is a dihydropyrrolidones derivative and is a potent inhibitor against wide subtypes of influenza A virus (IAV) with IC₅₀ values from 3.11 μM to 7.13 μM. Influenza A virus-IN-1 efficiently inhibits replication of *IAV*, up-regulates the expression of key antiviral cytokines IFN-β and antiviral protein MxA .

HY-158097

IAV-IN-2	Influenza Virus	Infection
IAV-IN-2 (Compound MC-22) inhibits for Influenza A Virus (IAV) through blocking the entry of IAV into host cell via clathrin-mediated endocytosis (CME) .

HY-177791

vRNPs degrader-1	PROTACs Influenza Virus	Infection
vRNPs degrader-1 is a potent PROTAC viral ribonucleoproteins (vRNPs) degrader. vRNPs degrader-1 shows broad-spectrum anti-influenza A viruses (IAV) activity by targeting the conserved 5′ end of viral RNA, thereby inducing proteasomal degradation of viral proteins. vRNPs degrader-1 inhibits H1N1, H9N2, and H3N2 infection in mice. vRNPs degrader-1 can be used for influenza research .

HY-169924

IAV replication-IN-1	Influenza Virus	Cancer
IAV replication-IN-1 (compound 3h) is reduce the upregulation of inflammatory factors and apoptosis induced by IAV infection.alleviate the lung injury caused by IAV infection .

HY-100858

PP7	Influenza Virus	Infection
PP7 is a potent PB1-PB2 interaction inhibitor with an IC₅₀ of 8.6 μM, and their inhibition against viral polymerase activity (IC₅₀=9.5 μM). PP7 shows antiviral activities against influenza A virus (IAV), including A(H1N1)pdm09 (EC₅₀=1.4 μM), A(H7N9) and A(H9N2) subtypes .

HY-175808

VF-57a	Influenza Virus	Infection
VF-57a (Compound 23) is an *Influenza A virus (IAV) fusion* inhibitor. VF-57 has potent antiviral activities against authentic A/H1N1 virus with EC₅₀s of 0.92 and 0.31 μM for the A/H1N1 PR8 and A/H1N1 Virg09 strains, respectively. VF-57 significantly inhibits HA-mediated cell entry of A/H1N1- and A/H5N1-pseudoviruses, prevents the HA refolding at pH 5.2. VF-57a can be used for IAV infections research .

HY-175559

TTHP 512	Influenza Virus	Infection
TTHP 512 is an influenza A virus (IAV) inhibitor. TTHP 512 demonstrates significant antiviral activity with an IC₅₀ value of 1.46 μM. TTHP 512 inhibits the expression of viral nucleoprotein (NP) and PB2 protein, thereby disrupting the viral replication process. TTHP 512 is promising for research of influenza A virus .

HY-149034

Influenza A virus-IN-8 S5	Influenza Virus	Infection Cancer
Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC₅₀s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a K_d of 1.0 nM .

HY-143495

RSV-IN-3	RSV Influenza Virus	Infection
RSV-IN-3 (Compound 1) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-3 shows anti-RSV activity (EC₅₀ = 32.70 μM) .

HY-143496

RSV-IN-4	RSV Influenza Virus	Infection
RSV-IN-4 (Compound 2) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza virus A (IAV). RSV-IN-4 shows anti-RSV activity (EC₅₀ = 11.76 μM) .

HY-128965R

N-Glycolylneuraminic acid (Standard) NeuGc (Standard); GcNeu (Standard)	Reference Standards Influenza Virus Endogenous Metabolite	Infection Cancer
N-Glycolylneuraminic acid (Standard) is the analytical standard of N-Glycolylneuraminic acid. This product is intended for research and analytical applications. N-Glycolylneuraminic acid is a nonhuman sialic acid molecule synthesized in pigs but not in humans. N-Glycolylneuraminic acid works as a decoy receptor of N-Glycolylneuraminic acid-binding influenza A viruses (IAVs) .

HY-135766

Colletodiol (+)-Colletodiol	Influenza Virus	Infection
Colletodiol is a fungal metabolite that has been found in D. grovesii and has immunosuppressant and antiviral activities. It inhibits concanavalin A- or LPS-induced proliferation of isolated mouse splenocytes (IC₅₀s=12 and 5 μg/mL, respectively).1 Colletodiol inhibits influenza A viral replication in HeLa-IAV-Luc cells.

HY-155514

HA-IN-1	Influenza Virus	Inflammation/Immunology
HA-IN-1 (compound 5g) is a Hemagglutinin (HA) ligand with high affinity, targeting to the trypsin cleavage site of HA. HA-IN-1 inhibits HA-mediated membrane fusion and reduces the pulmonary virus titer in vivo. HA-IN-1 is a potential influenza A virus (IAV) inhibitor, and an anti-influenza agent .

HY-163364

DS-22-inf-021	Influenza Virus	Infection
DS-22-inf-021 is a neuraminidase (NA) inhibitor. DS-22-inf-021 has antiviral activity against influenza viruses .

HY-170646

Influenza A virus-IN-15	Influenza Virus	Infection
Influenza A virus-IN-15 (Compound 9b), a quinoline derivative, is a broad-spectrum inhibitor of influenza A viruses with acceptable cytotoxicity (IC₅₀: 0.88-6.33 μM). Influenza A virus-IN-15 can inhibit the transcription and replication of viral RNA and is used in research for its antiviral effects against influenza A viruses (IAV) .

HY-151267

SARS-CoV-2-IN-25	SARS-CoV	Infection
SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC₅₀ of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes .

HY-151267A

SARS-CoV-2-IN-25 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-25 (Compound CP026) disodium is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC₅₀ of 1.6 μM. SARS-CoV-2-IN-25 disodium inhibits enveloped viruses and liposomes .

HY-183313

IAV-IN-5	Influenza Virus Apoptosis NF-κB Interleukin Related NO Synthase Toll-like Receptor (TLR)	Infection
IAV-IN-5 is an orally active inhibitor of influenza A virus (IAV). IAV-IN-5 inhibits viral replication, blocks virus-induced apoptosis (Apoptosis), oxidative stress and cytokine storm, and regulates host immune signaling pathways. IAV-IN-5 reduces viral load and inflammatory cytokine levels in lung tissues of IAV-infected mouse models, alleviates body weight loss and pulmonary pathological damage. IAV-IN-5 can be used in studies related to influenza A virus infection .

HY-162701

Antiviral agent 58	SARS-CoV Influenza Virus RSV HSV	Infection
Antiviral agent 58 (Compound J1) is an orally active antiviral agent with broad-spectrum antiviral activity against enveloped viruses, including influenza A virus (IAV), respiratory syncytial virus (RSV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human coronavirus OC43 (HCoV-OC43), herpes simplex virus type 1 (HSV-1), and HSV-2 .

HY-162492

Influenza A virus-IN-14	Influenza Virus	Infection
Influenza A virus-IN-14 (Compound 37) is an inhibitor for influenza virus type A (IAV), which inhibits H1N1 with an EC₅₀ of 23 nM. Influenza A virus-IN-14 exhibits low cytotoxicity with CC₅₀ of more than 100 μM. Influenza A virus-IN-14 inhibits cytopathic effect and improves the survival rates of cell Calu3. Influenza A virus-IN-14 exhibits synergistic activity with the neuraminidase inhibitor Oseltamivir (HY-13317). Influenza A virus-IN-14 exhibits poor pharmacokinetic properties in CD-1 mouse .

HY-151269A

SARS-CoV-2-IN-23 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-23 disodium is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 disodium exhibits antiviral activity with IC₅₀s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 disodium induces liposomal membrane disruption with an EC₅₀ value of 4.4 μM .

HY-151269

SARS-CoV-2-IN-26	SARS-CoV	Infection
SARS-CoV-2-IN-23 is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 exhibits antiviral activity with IC₅₀s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 induces liposomal membrane disruption with an EC₅₀ value of 4.4 μM .

HY-151276A

SARS-CoV-2-IN-29 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-29 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 disodium exhibits antiviral activity with IC₅₀s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 disodium induces liposomal membrane disruption with an EC₅₀ value of 3.0 μM .

HY-151278

SARS-CoV-2-IN-30	SARS-CoV	Infection
SARS-CoV-2-IN-30 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 exhibits antiviral activity with IC₅₀s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 induces liposomal membrane disruption with an EC₅₀ value of 6.9 μM .

HY-151276

SARS-CoV-2-IN-29	SARS-CoV	Infection
SARS-CoV-2-IN-29 is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 exhibits antiviral activity with IC₅₀s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 induces liposomal membrane disruption with an EC₅₀ value of 3.0 μM .

HY-151278A

SARS-CoV-2-IN-30 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-30 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-30 disodium exhibits antiviral activity with IC₅₀s of 0.6 μM and 6.9 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-30 disodium induces liposomal membrane disruption with an EC₅₀ value of 6.9 μM .

HY-151274

SARS-CoV-2-IN-28	SARS-CoV	Infection
SARS-CoV-2-IN-28 is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 exhibits antiviral activity with IC₅₀s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 induces liposomal membrane disruption with an EC₅₀ value of 4.4 μM .

HY-151274A

SARS-CoV-2-IN-28 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-28 disodium is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 disodium exhibits antiviral activity with IC₅₀s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 disodium induces liposomal membrane disruption with an EC₅₀ value of 4.4 μM .

HY-151271

SARS-CoV-2-IN-27	SARS-CoV	Infection
SARS-CoV-2-IN-27 is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 exhibits antiviral activity with IC₅₀s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 induces liposomal membrane disruption with an EC₅₀ value of 6.5 μM .

HY-151271A

SARS-CoV-2-IN-27 disodium	SARS-CoV	Infection
SARS-CoV-2-IN-27 disodium is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 disodium exhibits antiviral activity with IC₅₀s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 disodium induces liposomal membrane disruption with an EC₅₀ value of 6.5 μM .

Cat. No.	Product Name	Target	Research Area